1. Centers for Disease Control and Prevention. Childhood obesity facts. 2022. https://www.cdc.gov/obesity/data/childhood.html. Accessed 24 July 2022.
2. Styne DM, Arslanian SA, Connor EL, et al. Pediatric obesity-assessment, treatment, and prevention: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2017;102(3):709–57.
3. VIVUS LLC. QSYMIA (phentermine and topiramate extended-release capsules): US prescribing information. 2022. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/022580s021lbl.pdf. Accessed 18 July 2022.
4. VIVUS LLC. FDA approves QSYMIA® for the treatment of obesity in adolescents ages 12–17 [media release]. 20 July 2022. https://ir.vivus.com/news-releases/news-release-details/fda-approves-qsymiar-treatment-obesity-adolescents-ages-12-17.
5. Catalent Pharma Solutions. Catalent enters into commercial supply agreement with VIVUS for Qsymia™ once-daily combination-extended-release capsules [media release]. 2 Oct 2012. https://www.catalent.com.